Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe Seegraf. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources.